Local injection of micro‐dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment

International Journal of DermatologyVolume 63, Issue 4 p. 547-548 Letter to the Editor Local injection of micro-dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment YuFei Wang, YuFei Wang orcid.org/0009-0005-9936-7607 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorChaoJing Zhou, ChaoJing Zhou orcid.org/0000-0001-6854-1530 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorYiYun Hou, YiYun Hou Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorZiYue Diao, ZiYue Diao Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorDanDan Chen, DanDan Chen Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorZhiQiang Yin MD, PhD, Corresponding Author ZhiQiang Yin MD, PhD [email protected] orcid.org/0000-0002-6510-1051 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this author YuFei Wang, YuFei Wang orcid.org/0009-0005-9936-7607 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorChaoJing Zhou, ChaoJing Zhou orcid.org/0000-0001-6854-1530 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorYiYun Hou, YiYun Hou Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China These authors contributed equally to this work.Search for more papers by this authorZiYue Diao, ZiYue Diao Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorDanDan Chen, DanDan Chen Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorZhiQiang Yin MD, PhD, Corresponding Author ZhiQiang Yin MD, PhD [email protected] orcid.org/0000-0002-6510-1051 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this author First published: 16 January 2024 https://doi.org/10.1111/ijd.17036 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020; 34: 2330–2338. 10.1111/jdv.16265 CASPubMedWeb of Science®Google Scholar 2Smith MP, Ly K, Thibodeaux Q, Bhutani T, Liao W, Beck KM. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl). 2019; 9: 65–72. 10.2147/PTT.S180608 CASPubMedGoogle Scholar 3Xia RY, Liu J, Chen DD, Diao ZY, Gao YM, Yin ZQ. Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis. Indian J Dermatol. 2023; 68: 234. PubMedWeb of Science®Google Scholar 4Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2023; 47: 39–57. https://doi.org/10.1007/s40264-023-01361-w 10.1007/s40264-023-01361-w PubMedWeb of Science®Google Scholar 5Xia R, Liu J, Gao Y, Diao ZY, Chen DD, Zhou CJ, et al. Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: a real-world study. Clin Immunol. 2023; 253:109694. 10.1016/j.clim.2023.109694 CASPubMedWeb of Science®Google Scholar Volume63, Issue4April 2024Pages 547-548 ReferencesRelatedInformation